When does the Gazyva (obinutuzumab) patent expire?
Gazyva’s U.S. patent protection is centered on patents covering the antibody product and its use, with a likely timeline of exclusivity ending in the late 2020s to early 2030s depending on the exact patent and jurisdiction. However, the exact expiry date for “the” Gazyva patent family can’t be stated precisely from the information provided here.
Which patents are in the Gazyva obinutuzumab patent family?
“Patent family” can mean different things in practice: a set of related filings (same priority) across countries, or a cluster of separate U.S./EP/WO patents that cover different claims (composition, manufacturing, dosing, methods of treatment). Without the specific patent numbers or a source list, the full family membership for Gazyva cannot be verified.
How do you find the correct expiry date for the exact Gazyva patent family?
To get a precise expiry date, you typically need at least one of the following:
- A specific patent number (e.g., U.S. patent no.) you care about
- A WO publication number or EP publication number in the same family
- The INPADOC/PAIR record or a patent landscape listing that maps each family to its member jurisdictions and claim types
Once you have that, expiry is calculated from factors like:
- Filing and priority dates (basic term)
- Any patent-term adjustments/extension (jurisdiction-specific)
- Extension regimes (e.g., supplementary protection certificates in Europe, or exclusivity rules in the U.S.)
What if you mean “patent expiry” vs “regulatory exclusivity”?
For biologics like obinutuzumab, “market exclusivity end date” can differ from “last patent expiry date”:
- Patents can expire while regulatory exclusivity still blocks biosimilar entry.
- Biosimilar entry depends on the date regulatory barriers are cleared, not only patent expiry.
If you’re tracking biosimilar entry risk for Gazyva, you must map both:
1) the last relevant patent(s) in the family, and
2) the relevant regulatory exclusivity/approval pathway timing.
What I need to give you the exact Gazyva (obinutuzumab) patent-family expiry dates
Share any one of the following and I can return the exact expiry dates and the family members/jurisdictions:
- The patent numbers (U.S. / EP / WO) you’re looking for, or
- The INPADOC family ID / publication numbers, or
- The jurisdiction (U.S., EU/UK, etc.) and whether you want “earliest in family” or “latest-to-expire member.”
Sources
No sources were provided with the prompt, so no citations can be included.